Nucleus RadioPharma, Inc. announced that it will issue 10,547,047 series A preferred shares at issue price of $5.8879 per share for the gross proceeds of $62,099,958.0313 in funding on September 15, 2023. The shares are convertible and non-redeemable. The shares will be convertible into common shares at a price of $5.8879 per share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
78.02 USD | -0.70% | -1.65% | +0.91% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.91% | 35.86B | |
+7.01% | 215B | |
+11.01% | 187B | |
+19.20% | 143B | |
+30.79% | 110B | |
+1.48% | 64.68B | |
+13.95% | 52.96B | |
-0.16% | 49.84B | |
-6.20% | 38.32B | |
+19.95% | 30.75B |
- Stock Market
- Equities
- GEHC Stock
- News GE HealthCare Technologies Inc.
- Nucleus RadioPharma, Inc. announced that it expects to receive $62.099958 million in funding